▲ Peaking
Business
uniQure stock crashes as Huntington’s gene therapy data weaken
uniQure stock plunges following disappointing trial data for its Huntington’s disease gene therapy.
Clearpoint Neuro
1 trends tracked about this subject — the full history, oldest to newest below.